Description

Technical Parameters

Prostamax 20mg/bottle core introduction

Pharmaceutical-grade peptide formulations | Made in China, prostate health-targeting peptide 20mg/vial

Specifications : 20mg/bottle, 5 bottles/box

Purity : ≥99% (HPLC detection)

Appearance : White lyophilized powder

Storage : Refrigerate at 2-8℃, protected from light. Use within 7 days after reconstitution.

Core advantages and functions

Prostamax is a prostate tissue-targeting regulatory peptide that demonstrates unique value in the fields of benign prostatic hyperplasia (BPH) research, prostate health maintenance, and urinary system research by specifically regulating prostate cell proliferation, apoptosis, and inflammatory response pathways . It is an important tool peptide for urological and men's health research .

✅Prostate regulatory mechanism :

Cell proliferation regulation : regulating the growth cycle of prostate epithelial cells and smooth muscle cells

Inflammation response suppression : Downregulation of pro-inflammatory factors such as TNF-α, IL-6, and COX-2 in prostate tissue

Oxidative stress protection : Enhancing the antioxidant defense system of prostate cells

Regulation of angiogenesis : Controlling the expression of vascular endothelial growth factor (VEGF)

✅Quality advantages of Chinese manufacturers :

Sequence Design : Optimized Design Based on Prostate-Specific Membrane Antigen (PSMA) Target Sequences

Synthesis process : Fmoc solid-state synthesis combined with microwave-assisted synthesis technology

Purification control : Preparative HPLC combined with reversed-phase chromatography, main peak purity ≥ 99.5%.

Activity validation : Dual validation using in vitro prostate cell models and animal models

Aseptic production : Class C clean environment, automated filling and freeze-drying system

Quality Control Documents : Provide complete quality study documents (CMC document package).

✅Product Features :

Tissue targeting : Highly specific for prostate tissue

Metabolic stability : Enhanced enzymatic hydrolysis stability through D-amino acid modification.

Strong penetration : Optimized lipid solubility enhances tissue penetration ability.

Good safety profile : Preclinical safety studies show a good therapeutic index.

Usage and Storage Guide

1. Reconstitution and preparation :

Solvent selection :

First choice: Sterile saline

In vitro studies: serum-free cell culture media (RPMI-1640, DMEM, etc.)

Special study: PBS buffer containing 1-2% BSA

Standard configuration :

Pour 2 mL of solvent into the 20 mg vial and gently swirl to dissolve.

A stock solution of 10 mg/mL was obtained .

For lower concentrations, dilute gradually with the appropriate solvent.

Dissolving Notes :

Dissolving time: Approximately 3-5 minutes for complete dissolution.

Observation: The solution should be clear and transparent, free of particulate matter.

Contraindications: Avoid vigorous shaking, ultrasonic treatment, or heating to dissolve.

2. Storage conditions :

Unopened :

Store at 2-8℃ for 24 months .

Store frozen at -20℃ for 36 months .

Avoid repeated freeze-thaw cycles

Reconstituted :

Stock solution: Stable for 7 days when refrigerated at 2-8℃.

Working solution: It is recommended to prepare and use immediately, and store at 4°C for no more than 24 hours.

For long-term storage, repackage and freeze at -20°C.

Transportation conditions :

Cold chain transportation (2-8℃)

Uses professional temperature-controlled packaging

Inspect the goods immediately upon arrival and store them as required.

stability :

Most stable at pH 6.5-7.5

Temperature sensitivity: Avoid temperatures above 37°C

Photosensitivity: Sensitive to ultraviolet light, requires handling in the absence of light.

3. Research and application plan :

In vitro cell experiments :

Recommended concentration: 0.1-10 µM

Processing time: 24, 48, 72 hours

Cell type:

Human prostate epithelial cells (RWPE-1)

Human prostate cancer cells (LNCaP, PC-3)

Prostate fibroblasts

Evaluation indicators:

Cell proliferation (CCK-8, MTT)

Apoptosis (Annexin V/PI)

Cell cycle (PI staining flow cytometry)

Inflammatory factors (ELISA, qPCR)

Animal in vivo studies :

Recommendation model :

Testosterone-induced benign prostatic hyperplasia (BPH) rat model

Spontaneous BPH model (older dogs)

Prostatitis model

Route of administration :

Subcutaneous injection: 0.5-2.0 mg/kg , once daily.

Intraperitoneal injection: 0.2-1.0 mg/kg , once daily.

Oral administration: requires an appropriate delivery system.

Dosage regimen :

Prophylactic medication: Begin 1 week before modeling and continue for 4-8 weeks.

Therapeutic administration: Begins after modeling and continues for 2-6 weeks.

Evaluation indicators :

Prostate index (prostate weight/body weight)

Histopathology (HE staining, Masson staining)

Serum PSA level

Urodynamics

Inflammatory factor expression

Mechanism of action study :

Signaling pathways: Wnt/β-catenin, TGF-β/Smad, NF-κB

Hormone metabolism: 5α-reductase and aromatase activities

Extracellular matrix: Collagen deposition, degree of fibrosis

Angiogenesis: Microvessel density, VEGF expression

4. Experimental Design Suggestions :

Dosage exploration :

Low-dose group: 0.1 mg/kg

Medium dose group: 0.5 mg/kg

High-dose group: 2.0 mg/kg

Control group setup :

Blank control: physiological saline

Model comparison: Modeling + Solvent

Positive controls: finasteride (5 mg/kg) or doxazosin (0.5 mg/kg)

Sampling time :

Short-term effects: 1-7 days after administration

Mid-term effect: 2-4 weeks after administration

Long-term effects: 6-8 weeks after administration

Sample processing :

Prostate tissue: fixed with 4% paraformaldehyde (pathological), flash-frozen in liquid nitrogen (molecular).

Serum: Store at -80℃ after separation.

Urine: Freshly tested or stored at -20°C

Why choose Prostamax, made in China?

Technical advantages :

Possesses independent design capabilities for prostate-specific peptides.

Mature chemical modification techniques enhance stability

A comprehensive activity screening and validation platform

Quality Guarantee :

Strict raw material control: monitoring the entire process from starting materials to finished products.

Advanced analytical equipment: UPLC-MS/MS, CD, NMR, etc.

Complete stability study: accelerated and long-term stability data

Cost advantage :

Large-scale production reduces unit costs

Prices are 30-50% lower than similar imported products.

Offers customized packaging and size options.

Service Support :

Professional technical support team

Provide detailed experimental protocol reference

Comprehensive after-sales service system

Respond quickly to customer needs

Research and application directions

Basic research fields :

Molecular regulatory mechanisms of prostate growth

Hormone-dependent and non-hormone-dependent growth pathways

Prostate microenvironment and disease progression

The relationship between inflammation and benign prostatic hyperplasia

Translational medicine research :

Development of novel treatment strategies for prostate diseases

Design and evaluation of targeted drug delivery systems

Optimization of combination therapy regimens

Discovery and validation of biomarkers

Preclinical studies :

Drug efficacy and safety evaluation

Pharmacokinetic/Pharmacodynamic Studies

The mechanism of action was elucidated in depth.

Determining the optimal dosing regimen

Summarize

Prostamax embodies China's technological achievements in the research and development of urinary system-targeted peptide drugs . Through innovative peptide design, rigorous production control, and systematic activity validation , we provide high-quality, highly active research tools for urologists and men's health researchers worldwide . This product has significant application value in basic research and drug development for prostate diseases and is expected to drive scientific progress in this field.

Need anything, please contact us